英国老年人群带状疱疹疫苗接种效果评价
基于英国1933至1946年出生人群的链接初级保健记录队列研究,覆盖2013年9月1日至2016年8月31日疫苗接种规划前三年,共516,547人,21%已接种。调整后疫苗对带状疱疹发病的保护效果为64%(95%CI=60-68%),对带状疱疹后神经痛为81%(95%CI=61-91%),且随时间推移效果有所减弱。
要点
- 带状疱疹疫苗对发病的保护效果为64%(95%CI=60-68%),对带状疱疹后神经痛为81%(95%CI=61-91%)。
- 有带状疱疹既往史者疫苗效果较低:47%(95%CI=31-58%) vs 无既往史者64%(95%CI=60-68%)。
- 疫苗效果随时间减弱:接种后第一年69%(95%CI=65-74%),第三年降至45%(95%CI=29-57%)。
核心结论
- 这是英国带状疱疹疫苗接种规划首次正式效果评估,显示疫苗对带状疱疹有良好效果,对带状疱疹后神经痛有非常好的保护。
- 研究结果为英国带状疱疹疫苗接种规划的未来方向提供关键信息,提示减毒活带状疱疹疫苗可能比既往估计更具成本效果。
- 研究也支持传播带状疱疹疫苗接种益处的努力,以应对英国各地观察到的接种覆盖率下降。
研究设计与样本
- 基于人群的队列研究,纳入1933年至1946年出生的老年人,使用英国匿名化链接初级保健记录,覆盖疫苗接种规划前三年(2013年9月1日至2016年8月31日)。
- 采用多变量泊松回归获得发病率与疫苗效果(VE),共纳入516,547人,其中21%已接种疫苗。
主要发现
- 带状疱疹发病率在接种者中为3.15/1000人年,在未接种者中为8.80/1000人年。
- 调整后疫苗对带状疱疹发病的保护效果为64%(95%CI=60-68%),对带状疱疹后神经痛的保护效果为81%(95%CI=61-91%),常规队列与补种队列的VE估计非常相似。
- 有带状疱疹既往史者疫苗对带状疱疹的保护效果为47%(95%CI=31-58%),无既往史者为64%(95%CI=60-68%)。
- 疫苗效果随时间减弱:接种后第一年为69%(95%CI=65-74%),至第三年降至45%(95%CI=29-57%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccination against herpes zoster was introduced in the United Kingdom in 2013 for individuals aged 70 years, with a phased catch-up campaign for 71-79 year olds. Vaccine introduction has resulted in a marked fall in incident herpes zoster and in post-herpetic neuralgia (PHN), but formal evaluation of vaccine effectiveness is needed. METHODS: In a population-based cohort study of older individuals born between 1933 and 1946, we used linked UK anonymised primary care health records for the first three years of the vaccination programme (01/09/2013-31/08/2016) and multivariable Poisson regression to obtain incidence rates and vaccine effectiveness (VE) against zoster and PHN. RESULTS: Among 516,547 individuals, 21% were vaccinated. Incidence of zoster was 3.15/1000 person-years in vaccinees and 8.80/1000 person-years in unvaccinated individuals. After adjustment, VE was 64% (95%CI = 60-68%) against incident zoster and 81% (95%CI = 61-91%) against PHN, with very similar VE estimates in the routine and catch-up cohorts. VE against zoster was lower in those with a previous history of zoster: 47% (95%CI = 31-58%) versus 64% (95%CI = 60-68%) in those without previous zoster. There was evidence of waning VE over time, from 69% (95%CI = 65-74%) in the first year after vaccination to 45% (95%CI = 29-57%) by the third year. CONCLUSION: This first formal assessment of VE in the UK zoster vaccination programme demonstrates good effectiveness of zoster vaccine, and very good protection against PHN. The findings provide evidence that VE is similar across the age groups targeted for vaccination in the UK, and on duration of protection of the vaccine in public health use. The study provides key information for decision-makers about the future direction of UK zoster vaccination programme, indicating that the live zoster vaccine may be more cost-effective than estimated previously. It also supports efforts to communicate the benefits of zoster vaccination to address the declining coverage observed across the UK.
引用
- Walker JL, Andrews NJ, Amirthalingam G, et al. Effectiveness of herpes zoster vaccination in an older United Kingdom population. Vaccine. 2018. PMID: 29555217. doi:10.1016/j.vaccine.2018.02.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。